NASDAQ:VCNX

Vaccinex Stock Insider Trading

Healthcare > Biotechnology

Buy VCNX

*Your capital is at risk

$0.85

+0.0181 (+2.19%)

At Close: Jul 31, 2026

Vaccinex Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 5.37M and sold 0 VCNX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	5.37M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 18, 2024 Buy	Common Stock M-Exempt	Zauderer Maurice President And CEO	CEO / President	29 557 Value: $166.6K
Sep 18, 2024 Buy	Common Stock M-Exempt	Zauderer Maurice President And CEO	CEO / President	9 768 Value: $55.1K
Sep 18, 2024 Buy	Common Stock M-Exempt	Zauderer Maurice President And CEO	CEO / President	35 715 Value: $201.3K
Aug 09, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	100 Value: $451
Aug 09, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	100 Value: $451
Aug 06, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	2 753 Value: $13.5K
Aug 06, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	2 753 Value: $13.5K
Aug 05, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	3 653 Value: $16.8K
Aug 05, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	3 653 Value: $16.8K
Aug 01, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	11 703 Value: $55.2K
Aug 01, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	11 703 Value: $55.2K
Jul 31, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	16 128 Value: $119.3K
Jul 31, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	83 243 Value: $533.6K
Jul 31, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	100 629 Value: $577.4K
Jul 31, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	100 629 Value: $577.4K
Jul 31, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	83 243 Value: $533.6K
Jul 31, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	16 128 Value: $119.3K
May 30, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	861 Value: $4K
May 30, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	861 Value: $4K
May 29, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	957 Value: $5K
May 29, 2024 Buy	Common Stock P-Purchase	Friedberg Albert	Director	957 Value: $5K
May 10, 2024 Buy	Stock Option (Right to Buy) A-Award	Yanni Barbara Director	Director	10 108 Value: $58.1K
May 10, 2024 Buy	Stock Option (Right to Buy) A-Award	Van Strydonck, Gerald E. Director	Director	10 108 Value: $58.1K
May 10, 2024 Buy	Common Stock A-Award	Van Strydonck, Gerald E. Director	Director	543 Value: $3K
May 10, 2024 Buy	Stock Option (Right to Buy) A-Award	Manian Bala S Director	Director	10 108 Value: $58.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VACCINEX INC.

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatmen...

Read Full Profile Here